Back to Results

Amgen Inc (AMGN)

Amgen Inc. is a biotechnology company that develops, manufactures, and markets human therapeutics worldwide. Its portfolio includes treatments for conditions such as rheumatoid arthritis, psoriasis, osteoporosis, skeletal-related events, cardiovascular risk reduction, immune thrombocytopenia, multiple myeloma, anemia, thyroid eye disease, gout, and certain cancers and hematologic disorders. The company sells its products to healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies, and it relies on pharmaceutical wholesale distributors for distribution. Amgen also maintains collaboration arrangements with AstraZeneca, BeOne Medicines, UCB, Kyowa Kirin, and BeiGene tied to selected development and commercialization programs. Incorporated in 1980, Amgen is headquartered in Thousand Oaks, California, and its common stock is listed on the NASDAQ exchange under the symbol AMGN.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-AMGN
$391
7.2% Upside
Fair
$356.69
-2.2% Downside
Fair
Great
—
—
10.08
2.8%
August 4, 2026
25.3x
21.5x
5.3x
196.5 B
235.9 B
22.6%
99.7%
2.4
66.7%
110.2%
Send a message
Valuation • Fair Value

Amgen Inc (NASDAQ-AMGN) Fair Value by Valuation Model

Compare the primary fair value estimate for Amgen Inc (NASDAQ-AMGN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$391

Estimated upside of 7.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$428.93

Discounted cash flow valuation reference.

Ben Graham Formula Value

$160.36

Classic Ben Graham valuation formula reference.

DDM Fair Value

$495.84

Dividend discount model valuation reference.

EPV Fair Value

$256.86

Earnings power value estimate.

Comps Fair Value

$340.49

Comparable-company valuation reference.

Analyst Price Target

$356.69

Analysts imply downside of 2.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Amgen Inc (NASDAQ-AMGN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Amgen Inc (NASDAQ-AMGN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

37.22 B

Current operating scale indicator.

Revenue Forecast

37.669 B

Forward revenue estimate.

EBITDA

16.918 B

Current operating profitability reference.

EBITDA Forecast

21.456 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Amgen Inc (NASDAQ-AMGN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Amgen Inc (NASDAQ-AMGN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.55

No elevated caution signal from this screen.

Altman Z-Score

2.4

Intermediate risk zone.

FCF / Net Income

110.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Amgen Inc (NASDAQ-AMGN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Amgen Inc (NASDAQ-AMGN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 4, 2026

Days to Earnings

14

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

2.8%

Income yield reference.

Upcoming Dividend

10.08

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

66.7%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Amgen Inc (NASDAQ-AMGN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Amgen Inc (NASDAQ-AMGN) Stock Forecast & Technical Outlook

Review Amgen Inc (NASDAQ-AMGN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Amgen Inc (NASDAQ-AMGN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Amgen Inc (NASDAQ-AMGN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Amgen Inc (NASDAQ-AMGN) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Amgen Inc (NASDAQ-AMGN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Amgen Inc (NASDAQ-AMGN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Amgen Inc (NASDAQ-AMGN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Amgen Inc (NASDAQ-AMGN) has a Hold consensus, with 10 buy, 17 hold and 2 sell recommendations in the current data set.

Buy 10
Hold 17
Sell 2
FAQ • Fast Investor Answers

Amgen Inc (NASDAQ-AMGN) Stock FAQ

Quick answers about Amgen Inc (NASDAQ-AMGN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$391
Estimated upside 7.2%
Valuation Rating
Undervalued
Estimated upside of 7.2%
Analyst Target
$356.69
Implied downside 2.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for Amgen Inc (NASDAQ-AMGN) is $391. This implies an estimated upside of 7.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 7.2% versus the current market price.

The available analyst price target for Amgen Inc (NASDAQ-AMGN) is $356.69. The analyst target implies estimated downside of 2.2%.

The current financial health read for Amgen Inc (NASDAQ-AMGN) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Amgen Inc (NASDAQ-AMGN) is August 4, 2026.

Based on the current data, dividend yield is 2.8%, upcoming dividend amount is 10.08.

The current P/E ratio listed for Amgen Inc (NASDAQ-AMGN) is 25.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Amgen Inc is 196.5 B.

The current enterprise value listed for Amgen Inc is 235.9 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Amgen Inc is NASDAQ-AMGN, and the stock is listed on NASDAQ.

Amgen Inc (NASDAQ-AMGN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Amgen Inc is 22.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Amgen Inc is 99.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)
Cytokinetics Inc (CYTK) Cytokinetics Inc (CYTK)